{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T03:13:37Z","timestamp":1772594017577,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1038\/hr.2009.110","type":"journal-article","created":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T05:58:12Z","timestamp":1251957492000},"page":"738-740","source":"Crossref","is-referenced-by-count":42,"title":["Effects of angiotensin II receptor blockers on dementia"],"prefix":"10.1038","volume":"32","author":[{"given":"Masaki","family":"Mogi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,3]]},"reference":[{"key":"BFhr2009110_CR1","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","volume":"366","author":"CP Ferri","year":"2005","unstructured":"Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M . Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112\u20132117.","journal-title":"Lancet"},{"key":"BFhr2009110_CR2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1525-1497.2001.10123.x","volume":"16","author":"KM Langa","year":"2001","unstructured":"Langa KM, Chernew ME, Kabeto MU, Herzog AR, Ofstedal MB, Willis RJ, Wallace RB, Mucha LM, Straus WL, Fendrick AM . National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med 2001; 16: 770\u2013778.","journal-title":"J Gen Intern Med"},{"key":"BFhr2009110_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/ciia.2006.1.2.143","volume":"1","author":"CW Zhu","year":"2006","unstructured":"Zhu CW, Sano M . Economic considerations in the management of Alzheimer's disease. Clin Interv Aging 2006; 1: 143\u2013154.","journal-title":"Clin Interv Aging"},{"key":"BFhr2009110_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S1474-4422(05)70141-1","volume":"4","author":"C Qiu","year":"2005","unstructured":"Qiu C, Winblad B, Fratiglioni L . The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487\u2013499.","journal-title":"Lancet Neurol"},{"key":"BFhr2009110_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/j.clinthera.2007.09.019","volume":"29","author":"MR Weir","year":"2007","unstructured":"Weir MR . Effects of renin\u2013angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007; 29: 1803\u20131824.","journal-title":"Clin Ther"},{"key":"BFhr2009110_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/01.HYP.0000229648.67883.f9","volume":"48","author":"M Mogi","year":"2006","unstructured":"Mogi M, Li JM, Iwanami J, Min LJ, Tsukuda K, Iwai M, Horiuchi M . Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 2006; 48: 141\u2013148.","journal-title":"Hypertension"},{"key":"BFhr2009110_CR7","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995\u20131003.","journal-title":"Lancet"},{"key":"BFhr2009110_CR8","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","volume":"36","author":"J Schrader","year":"2005","unstructured":"Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC . Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218\u20131226.","journal-title":"Stroke"},{"key":"BFhr2009110_CR9","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1161\/01.STR.0000075777.18006.89","volume":"34","author":"J Schrader","year":"2003","unstructured":"Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P . The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699\u20131703.","journal-title":"Stroke"},{"key":"BFhr2009110_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/S0140-6736(07)60669-2","volume":"369","author":"S Mochizuki","year":"2007","unstructured":"Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N . Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity\u2013mortality study. Lancet 2007; 369: 1431\u20131439.","journal-title":"Lancet"},{"key":"BFhr2009110_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","volume":"46","author":"H Abuissa","year":"2005","unstructured":"Abuissa H, Jones PG, Marso SP, O'Keefe Jr JH . Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821\u2013826.","journal-title":"J Am Coll Cardiol"},{"key":"BFhr2009110_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/MJT.0b013e31804beb59","volume":"15","author":"MB Jibrini","year":"2008","unstructured":"Jibrini MB, Molnar J, Arora RR . Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther 2008; 15: 36\u201343.","journal-title":"Am J Ther"},{"key":"BFhr2009110_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/STROKEAHA.108.519801","volume":"40","author":"S Inaba","year":"2009","unstructured":"Inaba S, Iwai M, Tomono Y, Senba I, Furuno M, Kanno H, Okayama H, Mogi M, Higaki J, Horiuchi M . Exaggeration of focal cerebral ischemia in transgenic mice carrying human Renin and human angiotensinogen genes. Stroke 2009; 40: 597\u2013603.","journal-title":"Stroke"},{"key":"BFhr2009110_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/01.CIR.0000138848.58269.80","volume":"110","author":"M Iwai","year":"2004","unstructured":"Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M, Shiuchi T, Horiuchi M . Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110: 843\u2013848.","journal-title":"Circulation"},{"key":"BFhr2009110_CR15","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa060838","volume":"354","author":"S Julius","year":"2006","unstructured":"Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm Jr RH, Messerli FH, Oparil S, Schork MA . Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685\u20131697.","journal-title":"N Engl J Med"},{"key":"BFhr2009110_CR16","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1161\/STROKEAHA.107.503458","volume":"39","author":"JM Li","year":"2008","unstructured":"Li JM, Mogi M, Iwanami J, Min LJ, Tsukuda K, Sakata A, Fujita T, Iwai M, Horiuchi M . Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density. Stroke 2008; 39: 2029\u20132036.","journal-title":"Stroke"},{"key":"BFhr2009110_CR17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","volume":"52","author":"M de Gasparo","year":"2000","unstructured":"de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T . International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415\u2013472.","journal-title":"Pharmacol Rev"},{"key":"BFhr2009110_CR18","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1096\/fj.02-1193fje","volume":"17","author":"K Reinecke","year":"2003","unstructured":"Reinecke K, Lucius R, Reinecke A, Rickert U, Herdegen T, Unger T . Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J 2003; 17: 2094\u20132096.","journal-title":"FASEB J"},{"key":"BFhr2009110_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1096\/fj.04-2960fje","volume":"19","author":"J Li","year":"2005","unstructured":"Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, Blume A, Zimmermann M, Seidel K, Dirnagl U, Unger T . Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617\u2013619.","journal-title":"FASEB J"},{"key":"BFhr2009110_CR20","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1210\/mend.13.9.0344","volume":"13","author":"L Gendron","year":"1999","unstructured":"Gendron L, Laflamme L, Rivard N, Asselin C, Payet MD, Gallo-Payet N . Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999; 13: 1615\u20131626.","journal-title":"Mol Endocrinol"},{"key":"BFhr2009110_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3109\/07435809809032622","volume":"24","author":"F Cote","year":"1998","unstructured":"Cote F, Laflamme L, Payet MD, Gallo-Payet N . Nitric oxide, a new second messenger involved in the action of angiotensin II on neuronal differentiation of NG108-15 cells. Endocr Res 1998; 24: 403\u2013407.","journal-title":"Endocr Res"},{"key":"BFhr2009110_CR22","doi-asserted-by":"publisher","first-page":"31686","DOI":"10.1074\/jbc.274.44.31686","volume":"274","author":"F Cote","year":"1999","unstructured":"Cote F, Do TH, Laflamme L, Gallo JM, Gallo-Payet N . Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem 1999; 274: 31686\u201331692.","journal-title":"J Biol Chem"},{"key":"BFhr2009110_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1161\/HYPERTENSIONAHA.108.123612","volume":"53","author":"S Inaba","year":"2009","unstructured":"Inaba S, Iwai M, Furuno M, Tomono Y, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M . Continuous activation of renin-angiotensin system impairs cognitive function in renin\/angiotensinogen transgenic mice. Hypertension 2009; 53: 356\u2013362.","journal-title":"Hypertension"},{"key":"BFhr2009110_CR24","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1161\/HYPERTENSIONAHA.107.099374","volume":"50","author":"K Tsukuda","year":"2007","unstructured":"Tsukuda K, Mogi M, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M . Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan. Hypertension 2007; 50: 1099\u20131105.","journal-title":"Hypertension"},{"key":"BFhr2009110_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.neuropharm.2007.08.020","volume":"53","author":"M Mogi","year":"2007","unstructured":"Mogi M, Tsukuda K, Li JM, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M . Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Neuropharmacology 2007; 53: 899\u2013905.","journal-title":"Neuropharmacology"},{"key":"BFhr2009110_CR26","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1161\/01.HYP.0000163460.07639.3f","volume":"45","author":"K Kario","year":"2005","unstructured":"Kario K, Ishikawa J, Hoshide S, Matsui Y, Morinari M, Eguchi K, Ishikawa S, Shimada K . Diabetic brain damage in hypertension: role of renin-angiotensin system. Hypertension 2005; 45: 887\u2013893.","journal-title":"Hypertension"},{"key":"BFhr2009110_CR27","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1172\/JCI31547","volume":"117","author":"J Wang","year":"2007","unstructured":"Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, Humala N, Seror I, Bartholomew S, Rosendorff C, Pasinetti GM . Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 2007; 117: 3393\u20133402.","journal-title":"J Clin Invest"},{"key":"BFhr2009110_CR28","doi-asserted-by":"publisher","first-page":"47863","DOI":"10.1074\/jbc.M104068200","volume":"276","author":"J Hu","year":"2001","unstructured":"Hu J, Igarashi A, Kamata M, Nakagawa H . Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001; 276: 47863\u201347868.","journal-title":"J Biol Chem"},{"key":"BFhr2009110_CR29","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/archneur.63.5.noc60013","volume":"63","author":"AS Khachaturian","year":"2006","unstructured":"Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC . Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 2006; 63: 686\u2013692.","journal-title":"Arch Neurol"},{"key":"BFhr2009110_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(07)70077-7","volume":"6","author":"PG Kehoe","year":"2007","unstructured":"Kehoe PG, Wilcock GK . Is inhibition of the renin\u2013angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6: 373\u2013378.","journal-title":"Lancet Neurol"},{"key":"BFhr2009110_CR31","doi-asserted-by":"publisher","first-page":"T118","DOI":"10.1016\/j.jalz.2008.05.251","volume":"4","author":"B Wolozin","year":"2008","unstructured":"Wolozin B, Lee A, Lee A, Whitmer R, Kazis L . Use of angiotensin receptor blockers is associated with a lower incidence and progression of Alzheimer's disease. Alzheimers Dement 2008; 4: T118.","journal-title":"Alzheimers Dement"},{"key":"BFhr2009110_CR32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.bbrc.2008.08.032","volume":"375","author":"M Mogi","year":"2008","unstructured":"Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, Fujita T, Iwai M, Horiuchi M . Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 2008; 375: 446\u2013449.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"BFhr2009110_CR33","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/HYPERTENSIONAHA.109.136879","volume":"54","author":"Kana Tsukuda","year":"2009","unstructured":"Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M . Cognitive deficit in amyloid beta-injected mice was improved by pretreatment with a low dose of telmisartan partly due to PPAR-gamma activation. Hypertension 2009 (e-pub ahead of print 27 July; doi: 10.1161\/HYPERTENSIONAHA.109.136879).","journal-title":"Hypertension"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2009110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2009110","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2009110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T23:37:59Z","timestamp":1739317079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2009110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["BFhr2009110"],"URL":"https:\/\/doi.org\/10.1038\/hr.2009.110","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}